Browse ADAMTS12

Summary
SymbolADAMTS12
NameADAM metallopeptidase with thrombospondin type 1 motif, 12
Aliases a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 12; PRO4389; ADAM ......
Chromosomal Location5q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix
Domain PF05986 ADAM-TS Spacer 1
PF01562 Reprolysin family propeptide
PF01421 Reprolysin (M12B) family zinc metalloprotease
PF00090 Thrombospondin type 1 domain
Function

Metalloprotease that may play a role in the degradation of COMP. Cleaves also alpha-2 macroglobulin and aggregan. Has anti-tumorigenic properties.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0002062 chondrocyte differentiation
GO:0003158 endothelium development
GO:0003159 morphogenesis of an endothelium
GO:0006029 proteoglycan metabolic process
GO:0006516 glycoprotein catabolic process
GO:0007160 cell-matrix adhesion
GO:0009100 glycoprotein metabolic process
GO:0030167 proteoglycan catabolic process
GO:0031589 cell-substrate adhesion
GO:0032330 regulation of chondrocyte differentiation
GO:0032331 negative regulation of chondrocyte differentiation
GO:0034612 response to tumor necrosis factor
GO:0035239 tube morphogenesis
GO:0035728 response to hepatocyte growth factor
GO:0035729 cellular response to hepatocyte growth factor stimulus
GO:0035924 cellular response to vascular endothelial growth factor stimulus
GO:0048012 hepatocyte growth factor receptor signaling pathway
GO:0050727 regulation of inflammatory response
GO:0051216 cartilage development
GO:0060562 epithelial tube morphogenesis
GO:0061035 regulation of cartilage development
GO:0061037 negative regulation of cartilage development
GO:0061154 endothelial tube morphogenesis
GO:0061448 connective tissue development
GO:0070555 response to interleukin-1
GO:0071347 cellular response to interleukin-1
GO:0071356 cellular response to tumor necrosis factor
GO:0071772 response to BMP
GO:0071773 cellular response to BMP stimulus
GO:0090287 regulation of cellular response to growth factor stimulus
GO:0090288 negative regulation of cellular response to growth factor stimulus
GO:1901136 carbohydrate derivative catabolic process
GO:1901509 regulation of endothelial tube morphogenesis
GO:1902202 regulation of hepatocyte growth factor receptor signaling pathway
GO:1902203 negative regulation of hepatocyte growth factor receptor signaling pathway
GO:1902547 regulation of cellular response to vascular endothelial growth factor stimulus
GO:1902548 negative regulation of cellular response to vascular endothelial growth factor stimulus
GO:1905330 regulation of morphogenesis of an epithelium
GO:2001112 regulation of cellular response to hepatocyte growth factor stimulus
GO:2001113 negative regulation of cellular response to hepatocyte growth factor stimulus
Molecular Function GO:0004175 endopeptidase activity
GO:0004222 metalloendopeptidase activity
GO:0008237 metallopeptidase activity
Cellular Component GO:0005578 proteinaceous extracellular matrix
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-5083635: Defective B3GALTL causes Peters-plus syndrome (PpS)
R-HSA-1643685: Disease
R-HSA-3906995: Diseases associated with O-glycosylation of proteins
R-HSA-3781865: Diseases of glycosylation
R-HSA-392499: Metabolism of proteins
R-HSA-5173214: O-glycosylation of TSR domain-containing proteins
R-HSA-5173105: O-linked glycosylation
R-HSA-597592: Post-translational protein modification
Summary
SymbolADAMTS12
NameADAM metallopeptidase with thrombospondin type 1 motif, 12
Aliases a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 12; PRO4389; ADAM ......
Chromosomal Location5q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ADAMTS12 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolADAMTS12
NameADAM metallopeptidase with thrombospondin type 1 motif, 12
Aliases a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 12; PRO4389; ADAM ......
Chromosomal Location5q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ADAMTS12 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolADAMTS12
NameADAM metallopeptidase with thrombospondin type 1 motif, 12
Aliases a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 12; PRO4389; ADAM ......
Chromosomal Location5q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ADAMTS12 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.0330.00245
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.2270.0489
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.8860.0816
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.9250.0135
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.1320.552
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6580.793
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2070.711
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2550.782
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0650.951
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4120.665
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.9640.0809
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2480.274
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ADAMTS12 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1031033.3-23.30.423
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.86.880.247
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.88.56.30.453
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.511.8-2.31
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.516.7-4.21
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolADAMTS12
NameADAM metallopeptidase with thrombospondin type 1 motif, 12
Aliases a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 12; PRO4389; ADAM ......
Chromosomal Location5q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ADAMTS12. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolADAMTS12
NameADAM metallopeptidase with thrombospondin type 1 motif, 12
Aliases a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 12; PRO4389; ADAM ......
Chromosomal Location5q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ADAMTS12. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ADAMTS12.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolADAMTS12
NameADAM metallopeptidase with thrombospondin type 1 motif, 12
Aliases a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 12; PRO4389; ADAM ......
Chromosomal Location5q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ADAMTS12. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolADAMTS12
NameADAM metallopeptidase with thrombospondin type 1 motif, 12
Aliases a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 12; PRO4389; ADAM ......
Chromosomal Location5q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ADAMTS12 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolADAMTS12
NameADAM metallopeptidase with thrombospondin type 1 motif, 12
Aliases a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 12; PRO4389; ADAM ......
Chromosomal Location5q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ADAMTS12 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolADAMTS12
NameADAM metallopeptidase with thrombospondin type 1 motif, 12
Aliases a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 12; PRO4389; ADAM ......
Chromosomal Location5q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ADAMTS12 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.